Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients
Metadatos
Mostrar el registro completo del ítemEditorial
MDPI
Materia
Circulating tumor cell Cluster Portal vein Central venous catheter Pancreatic cancer Early stage Death risk stratification
Fecha
2021-12-07Referencia bibliográfica
Padillo-Ruiz, J... [et al.]. Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients. Cancers 2021, 13, 6153. [https://doi.org/10.3390/cancers13246153]
Patrocinador
Carlos III Health Institute (Health Research Fund) (European Regional Development Fund "A way to make Europe") PI16/01465 PI19/01821Resumen
Background. Effective biomarkers are needed to enable personalized medicine for pancreatic
cancer patients. This study analyzes the prognostic value, in early pancreatic cancer, of single
circulating tumor cell (CTC) and CTC clusters from the central venous catheter (CVC) and portal
blood (PV). Methods. In total, 7 mL of PV and CVC blood from 35 patients with early pancreatic
cancer were analyzed. CTC were isolated using a positive immunomagnetic selection. The detection
and identification of CTC were performed by immunocytochemistry (ICC) and were analyzed by
Epi-fluorescence and confocal microscopy. Results. CTC and the clusters were detected both in PV
and CVC. In both samples, the CTC number per cluster was higher in patients with grade three
or poorly differentiated tumors (G3) than in patients with well (G1) or moderately (G2) differentiated.
Patients with fewer than 185 CTC in PV exhibited a longer OS than patients with more than
185 CTC (24.5 vs. 10.0 months; p = 0.018). Similarly, patients with fewer than 15 clusters in PV showed
a longer OS than patients with more than 15 clusters (19 vs. 10 months; p = 0.004). These significant
correlations were not observed in CVC analyses. Conclusions. CTC presence in PV could be an
important prognostic factor to predict poor prognosis in early pancreatic cancer. In addition, the
number of clustered-CTC correlate to a tumor negative differentiation degree and, therefore, could
be used as a diagnostic biomarker for pancreatic cancer.